Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Cost Containment's Impact on Oncology Practices

April 26th 2015

Assessing the Cost of Cancer Care

April 26th 2015

Bundled Payments in Community Oncology

April 26th 2015

Moving Away From Traditional Payment Models in Oncology

April 26th 2015

Addressing Cancer Health Disparities

April 26th 2015

Reining in the Cost of Cancer Care

April 26th 2015

Reimbursement for Oncology Treatment

April 26th 2015

Bundled Payment Models for Cancer-Related Costs

April 26th 2015

US Cancer-Related Healthcare Costs on the Rise

April 26th 2015

A Community in Unity

April 26th 2015

The Emperor of All Maladies documentary did a great job of capturing the innovative genius of mankind and the heroism of both oncologists and the patients who participated in their research.

BRCA Questions Resound

April 26th 2015

Given the higher risk of breast and ovarian cancer in BRCA mutation carriers, should broader screening for the abnormality be implemented?

Broad BRCA Screening is Becoming a Thorny Public Health Issue

April 23rd 2015

Population-based cancer screening using genetic sequencing technology is an idea worthy of careful consideration, but there are many challenges to implementing such a program.

Physician Quandary: Data Shortage, Surfeit Impinge on Precision Medicine

April 18th 2015

Like all new ideas or technologies, rapidly occurring changes present both opportunities and challenges for everyone involved, including government, patients, payers and physicians.

Oral Fluoropyrimidine TAS-102 in Refractory mCRC

April 16th 2015

Use of Regorafenib in Refractory mCRC

April 16th 2015

Second-Line Therapy for RAS Wild-Type mCRC

April 16th 2015

Choosing Between VEGF and EGFR Targeted Therapy in mCRC

April 16th 2015

Newly Diagnosed mCRC Treatment Goals

April 16th 2015

Dr. LoRusso on Personalized Medicine for Melanoma

April 15th 2015

Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

The Genetic Landscape of Pancreatic Cancer

April 8th 2015